E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
metastatic colorectal cancer |
|
E.1.1.1 | Medical condition in easily understood language |
colorectal cancer with metastasis |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10052362 |
E.1.2 | Term | Metastatic colorectal cancer |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
•To evaluate the prognostic relevance of relative changes in SUV (as measured in 18F-FDG PET-CT at day 14 versus baseline) for early clinical response (as defined by RECIST, measured at day 56) during short-term single agent treatment with the EGFR-mAB cetuximab |
|
E.2.2 | Secondary objectives of the trial |
• To investigate duration of PFS as well as the influence of changes in individual SUV and early clinical response on PFS. • To investigate duration of OS and its association with SUV. • The assessment of antivascular/antiangiogenic effects of cetuximab by contrast-enhanced ultrasound. • This clinical trial will include an accompanying research component involving collection of biological samples for pseudonymized analyses. These will comprise sequential serum protein marker assessments (e.g. multiplex cytokine immune monitoring) as well as baseline analysis of tumor proteins and tumor genes, (like e.g. PTEN expression, mutations in EGFR dependent downstream kinases like PI-3-kinase, BRAF and EGFR gene expression as measured by fluorescence-in-situ-hybridization). Patients may participate in this study even if they choose not to participate in this component.
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
There will be a sub-study. If special written informed consent for translational research is available, 20 ml of venous blood will be taken at baseline and on day 14 for cytokine immune monitoring during the study. The samples will immediately be brought to the processing laboratory at the NCT. PTEN and other tumor protein and tumor gene expression analyses will be performed on the existing pre-therapeutic biopsy specimen, if available. |
|
E.3 | Principal inclusion criteria |
• Histologically confirmed metastatic colorectal cancer • RAS-wildtype status of the tumor • No history of therapy with an EGFR targeting agent • No history of previous chemotherapy for advanced disease • Measurable tumor lesion with a diameter no smaller than 1.0 cm detected by CT, MRI or ultrasound • For contrast-enhanced ultrasound: metastases no smaller than 2.0 cm • ECOG-performance status 0 or 1 or Karnofsky performance scale min. 70% • Life expectancy > 12 weeks • Age ≥ 18 years • Adequate hematologic, renal and hepatic function • Ability of the patient to understand the character and individual consequences of this clinical trial • Written informed consent (must be available before enrolment in the trial) • For women and men with childbearing potential adequate double barrier contraception, for women: negative pregnancy test • Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
|
|
E.4 | Principal exclusion criteria |
• Any contraindications for chemotherapy according to the Folfiri regimen • Non-curatively treated malignancy within the last 5 years • Uncontrolled or insulin-dependent diabetes mellitus • Evidence of CNS metastases • Uncontrolled infection • Significant cardiac disease (unstable angina pectoris or cardiac symptoms according to NYHA classification III or IV) • Active serious illness which renders the patient unsuitable for study entry or multiple blood sampling • Pregnancy and lactation • History of hypersensitivity to cetuximab or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product • Participation in other competing clinical trials or observation period of competing trials, respectively • No patient will be allowed to enroll in this trial more than once.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary Endpoint: • Clinical response: Responders are defined as patients achieving partial or complete responses as measured by RECIST at day 56. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Endpoint will be evaluated by the following parameters: • Metabolic tumor response will be evaluated by means of 18F-FDG PET-CT on baseline and day 14 (after 2 weeks of single-agent treatment with cetuximab).
|
|
E.5.2 | Secondary end point(s) |
• To investigate duration of PFS as well as the influence of changes in individual SUV and early clinical response on PFS. • To investigate duration of OS and its association with SUV. • The assessment of antivascular/antiangiogenic effects of cetuximab by contrast-enhanced ultrasound.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
• Antivascular/ antiangiogenic effects of cetuximab (i. e., on relative blood volume and perfusion) will be evaluated by contrast-enhanced ultrasound on baseline and day 14. • Clinical response will be evaluated according to RECIST with a routine CT scan on day 56 in comparison with the baseline analysis. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Patients will be followed up until death
cut off date 24 months after last subject out |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | 0 |